Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13004683 | 0.86 | PIK3CG (0.51) | GRM5PIK3CGPIK3CA | |
| SCHEMBL13004673 | 0.85 | PIK3CG (0.65) | GRM5PIK3CGPIK3CA | |
| SCHEMBL3773164 | 0.83 | PIK3CG (0.53) | GRM5PIK3CGPIK3CACYP2C9PRKDC | |
| SCHEMBL13004693 | 0.81 | SMN1; SMN2 (0.47) | GRM5PIK3CGPIK3CA | |
| SCHEMBL13004708 | 0.80 | DYRK1A (0.47) | GRM5PIK3CGPIK3CACYP2C9PRKDC | |
| SCHEMBL12992020 | 0.80 | CLK1 (0.47) | GRM5PIK3CGPIK3CA | |
| SCHEMBL12992330 | 0.80 | PIK3CG (0.49) | PIK3CGPIK3CACYP2C9PRKDC | |
| SCHEMBL1702659 | 0.79 | PIK3CG (0.64) | PIK3CGPIK3CACYP2C9PRKDCKCNH2 | |
| SCHEMBL13004691 | 0.79 | PIK3CG (0.49) | PIK3CGPIK3CA | |
| SCHEMBL13004677 | 0.78 | PIK3CG (0.50) | GRM5PIK3CGPIK3CACYP2C9PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344153-B2 | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344153-B2 | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| CN-102548990-A | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMA | 2012-07-04 | — | — | CN | disclosed |
| EP-2440556-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144513-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CG, PIK3CD | GRM5 2543/4885PIK3CG 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.